

Product Name: Gliotoxin Revision Date: 01/10/2020

Product Data Sheet

Gliotoxin

Cat. No.: A4443 **CAS No.:** 67-99-2

Formula: C13H14N2O4S2


M.Wt: 326.38

Synonyms:

Target: Ubiquitination/ Proteasome

Pathway: Proteasome

Storage: Desiccate at -20°C



Solvent & Solubility

Soluble in DMSO

20S proteasome inhibitor

In Vitro

Shortsummary

Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
	1 mM	3.0639 mL	15.3196 mL	30.6391 mL
	5 mM	0.6128 mL	3.0639 mL	6.1278 mL
	10 mM	0.3064 mL	1.5320 mL	3.0639 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

	·				
IC ₅₀ & Target					
	Cell Viability Assay				
In Vitro	Cell Line:	breast cancer cell lines (MCF-7 and MDA-MB-231 cells)			
	Preparation method:	The solubility of this compound in DMSO is >10mM. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or			
		shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.			
	Reacting conditions:	1 nM to 10 μM			
	Applications:	Gliotoxin inhibited proliferation of six breast cancer cell lines in culture and			

		protein prenylation over the same range of concentrations. Treatment with		
		gliotoxin for 24 h led to a clear dose-dependent inhibition of Lamin B		
		farnesylation and Rap1A geranylgeranylation in breast cancer cell lines. Taken		
		together these findings indicated that the observed antitumor activity of		
		gliotoxin in breast cancer cell lines was most likely due to prenyltransferase		
		inhibition.		
	Animal experiment			
In Vivo	Animal models:	Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with		
		N-methyl-Nnitrosourea (NMU)		
	Dosage form:	from 1.25 to 25 mg/kg; subcutaneous injection; weekly for 4 wk.		
	Applications:	In all rats, all five gliotoxin-treated rats completing the study responded to		
		treatment, three of which had >50% tumor regression (partial response) and		
		two others with stable disease (<50% tumor regression) and the antitumor		
		effects of gliotoxin were manifest within the first week of treatment.		
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may		
		slightly differ with the theoretical value. This is caused by an experimental		
		system error and it is normal.		

Product Citations

1.Angelina C, Tan ISY, et al. "KIF1Bβ increases ROSto mediate apoptosis and reinforces its protein expression through O (2)(-) in apositive feedback mechanism in neuroblastoma." Sci Rep. 2017 Dec 4;7(1):16867.PMID:29203804

See more customer validations on www.apexbt.com.

References

[1]. Vigushin DM, Mirsaidi N, Brooke G., et al. Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumor activity against breast cancer in vivo. MEDICAL ONCOLOGY, 2004, 21(1):21-30.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

